The rapid global adoption of glucagon-like peptide-1 (GLP-1) receptor agonists—a class of medications that includes popular treatments for type 2 diabetes and obesity—has ushered in a new era of metabolic health management. However, as these drugs become household names, the medical community is beginning to scrutinize their secondary, and sometimes unexpected, systemic effects. A comprehensive new study published in JAMA Otolaryngology-Head & Neck Surgery has identified a statistically significant association between the use of GLP-1 receptor agonists and an increased risk of chemosensory disturbances, specifically affecting smell and taste.
Main Facts: The Link Between GLP-1 and Sensory Health
The analysis, led by researchers Nir Zontag and Jonathan Zontag of the Hadassah Medical Center at Hebrew University in Jerusalem, suggests that patients treated with GLP-1 agonists face a 48% higher risk of experiencing overall smell and taste disruptions compared to patients managing their type 2 diabetes with alternative therapies.
The study, which utilized extensive electronic health record (EHR) data, found that the increased risk was consistent across both categories of sensory dysfunction. Specifically, users of GLP-1 medications showed an 81% increased risk of smell disturbances—such as anosmia (total loss of smell) and parosmia (distorted sense of smell)—and a 52% increased risk of taste disturbances, such as parageusia (an unpleasant or altered sense of taste).
While these percentages sound dramatic, the researchers were careful to provide clinical context. The absolute risk increase for these conditions remained relatively small, at 0.08% for smell disturbances and 0.07% for taste disturbances. Nonetheless, the findings represent a critical signal that warrants further investigation, especially as the number of patients prescribed these agents continues to climb globally.
Chronology of Research and Data Analysis
To reach these conclusions, the Zontags conducted a massive retrospective study utilizing the TriNetX Global Collaborative Network. The research period spanned from December 2017 to April 2026, capturing a timeframe that mirrors the meteoric rise of drugs like semaglutide and tirzepatide.
The study design focused on adults diagnosed with type 2 diabetes who had no prior history of smell or taste dysfunction. To ensure robust comparison, the researchers utilized propensity-score matching, resulting in two cohorts of 438,474 patients each. The "exposure group" received at least one GLP-1 receptor agonist, while the "control group" was prescribed other common diabetes medications, including SGLT2 inhibitors, DPP-4 inhibitors, metformin, insulin, and sulfonylureas.
The average age of the participants was approximately 58 years, with a demographic split of 55% female. The two-year follow-up period allowed researchers to track the development of new sensory diagnoses, which were identified through standardized International Classification of Diseases (ICD) codes.
Supporting Data and Potential Mechanisms
The researchers proposed that the relationship between GLP-1 agonists and sensory impairment is likely multifactorial. GLP-1 receptors are not exclusive to the pancreas and the gut; they have been identified in the olfactory bulb and within the taste buds themselves. This biological distribution suggests that the medication could be interacting directly with the peripheral sensory receptors. Furthermore, the researchers noted that the drugs might influence central neural pathways responsible for processing olfactory and gustatory signals.
Historically, sensory disturbances in diabetic populations were almost exclusively attributed to diabetic neuropathy—the nerve damage that occurs over time due to chronic high blood sugar—or microvascular complications. However, this study adds to a growing body of evidence, including recent case reports, suggesting that the pharmacological action of GLP-1 agents themselves may be a contributing factor. As these drugs are known to be highly effective for weight loss and glycemic control, their mechanism of action is powerful, potentially triggering unintended physiological feedback loops in sensory organs.
Perspectives from the Clinical Community
The publication of these findings has drawn significant attention from the otolaryngology community. In an accompanying commentary, Dr. Charles Riley of Boston University and Dr. Edward McCoul of the Ochsner Clinic Foundation emphasized that sensory health is a vital indicator of systemic well-being.
"Olfactory dysfunction is one of the most reliable prodromal markers for neurodegenerative conditions such as Parkinson’s disease and Alzheimer’s disease," the editorialists noted. They stressed that smell and taste serve as an "essential sensory warning system," allowing individuals to detect environmental hazards like smoke, gas leaks, or spoiled food.
Dr. Riley and Dr. McCoul argued that while the absolute risk is small, the sheer scale of the patient population taking these drugs makes this a public health concern that clinicians cannot afford to ignore. They advocate for a shift in prescribing culture, moving toward a model of "shared decision-making" where the potential for sensory side effects is discussed openly during the informed consent process.
Implications for Future Patient Care
The findings from the Hadassah Medical Center team have clear implications for how physicians should approach patients initiating GLP-1 therapy. The editorialists offered a roadmap for clinical practice, recommending that:
- Baseline Assessment: Clinicians should conduct a subjective assessment of a patient’s current smell and taste abilities before initiating therapy.
- Ongoing Surveillance: Patients should be monitored for sensory changes throughout their treatment duration.
- Validated Testing: For high-risk individuals or those who report early signs of dysfunction, clinicians should consider using validated tools like the Smell Identification Test.
- Specialist Referral: If a patient reports persistent or worsening olfactory loss, a referral to an otolaryngologist is warranted to rule out other causes and evaluate the necessity of continuing the medication.
However, the authors of the study and the commentary authors alike were careful to emphasize that the benefits of GLP-1 agonists—particularly for patients with severe obesity, cardiovascular disease, or uncontrolled diabetes—often outweigh the risks of sensory side effects. The goal is not to discourage the use of these life-changing medications, but to optimize the safety profile through better patient monitoring.
Limitations and Future Research
Despite the scale of the study, the authors acknowledged several significant limitations. The reliance on ICD codes means that the study captured only those cases where a patient felt the issue was severe enough to report to a doctor, and where the doctor subsequently coded the visit. Because sensory disturbances are subjective, they are often under-reported or misattributed.
Additionally, the study grouped all GLP-1 receptor agonists into a single category. Future research, the authors noted, must account for the molecular differences between drugs like semaglutide, liraglutide, and tirzepatide, as these variations could lead to different side-effect profiles.
"We are likely in the early stages of a profound therapeutic shift," the commentary concluded. As the medical field continues to explore the "mechanistic frontiers" of GLP-1 agonists, prospective studies that include objective, baseline sensory testing will be essential. Researchers aim to move toward dose-response and duration-response analyses to determine if the risk is tied to the strength of the medication or the length of time a patient remains on the drug.
For now, the medical community has a new piece of the puzzle regarding the safety of GLP-1 agonists. As millions of patients continue their journeys toward metabolic health, the focus remains on ensuring that in the pursuit of a healthier weight and lower blood sugar, their other vital sensory functions are not overlooked.
